Mes données de santé

Strona informacyjna dla pacjentów leczonych w sieci Unicancer lub włączonych do badań klinicznych sieci Unicancer

O tej stronie

Cele

Impact of the histological margin quality at initial surgery (R0 from the outset vs. R0 after revision surgery) on local relapse-free survival;

a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

Administrator danych

Institut de Cancérologie de l'Ouest

Kategorie wykorzystywanych danych
Données d’identification (sans donnée nominative) / Données de santé
Origine de données utilisées
Soins
Institut de Cancérologie de l'Ouest (Nantes et Angers)
2010
2011
2012
2013
2014
2015
2016
2017
Populacja będąca przedmiotem badań lub przetwarzania danych

Cutaneous sarcoma of the base with a representation of more than 20 cases Patient who underwent a surgery of cutaneous sarcoma and whose file was included in the NETSARC database From 01/01/2010 to 30/12/2017

Podstawa prawna

 6.e) RGPD le traitement est nécessaire à l'exécution d'une mission d'intérêt public

Wewnętrzni i zewnętrzni odbiorcy danych

Institut de Cancérologie de l'Ouest

Data rozpoczęcia badania
02/11/2020
Okres przechowywania danych

Conservation pendant 2 ans après la valorisation (publication/article, these, présentation orale, poster, autre) des résultats de la recherche. Puis archivage avec un accès restreint aux personnes intervenant dans la recherche, pendant une durée limitée de 3 ans (5ans au total post publication)

W celu ochrony danych zdrowotnych zaleca się nieujawnianie w tym formularzu osobistych informacji zdrowotnych o sobie lub członku rodziny.
Zapraszamy do wskazania placówki, w której otrzymują Państwo opiekę, a my zapewnimy nawiązanie odpowiedniego połączenia w celu zagwarantowania realizacji Państwa prośby.
CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
Cette question sert à vérifier si vous êtes un visiteur humain ou non afin d'éviter les soumissions de pourriel (spam) automatisées.

Informacje zebrane w kwestionariuszu nie są przechowywane na tej stronie, ale są przesyłane do administratora danych wymienionego w formularzu badawczym. Dane te są zbierane w celu przetworzenia Państwa wniosku o realizację praw.

Dane oznaczone gwiazdką w kwestionariuszu muszą być obowiązkowo podane w celu przesłania formularza i przetworzenia Państwa wniosku.

Zebrane dane zostaną przekazane administratorowi Państwa danych i jego IOD w celu przetworzenia tych wniosków.

Są one przechowywane przez czas analizy i odpowiedzi na nią.Mają Państwo prawo dostępu do swoich danych osobowych, ich poprawiania i usuwania. Mogą Państwo również sprzeciwić się przetwarzaniu swoich danych.

Aby skorzystać z tych praw lub w przypadku jakichkolwiek pytań dotyczących przetwarzania Państwa danych, należy wypełnić ten formularz.

Jeśli uważają Państwo, po skontaktowaniu się z nami, że Państwa prawa do "Ochrony Danych" nie są respektowane, mogą Państwo złożyć skargę do właściwego organu ochrony danych.